Studies by other groups have demonstrated that CD4 T cells and/or NK1.1+ cells contribute to tumor protection in B16 tumor-bearing mice treated with anti-CD25 [36], [37], which could explain the absence of detectable CD8 T cell responses. This evidence concerns the gene CD8A and neoplasm.